Eurofins Discovery, a drug discovery services provider, and Shanghai, China-based, contract research organization (CRO), PharmaResources, announced a partnership to build a joint drug discovery platform that could help speed clinical development of small molecule drugs.
The therapeutic area in which the platform will assist in drug discovery was not specified, however, Eurofins announced that over 30 of PharmaResources’ client programs will benefit from the former’s in-vitro pharmacology and absorption, distribution, metabolism, and excretion (ADME) assessments.
As a result, the partners expect to provide earlier and faster access to safety and efficacy data to drug developers, ultimately improving R&D efficiency, with more than 300 of PharmaResources’ medicinal scientists accessing Eurofins’ technologies.
More specifically, Eurofins’ offering expands on a broad range of services including in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.
These services can potentially enable the targeting of G-protein-coupled receptors, kinases, ion channels, nuclear hormone receptors, as well as other proteins and enzymes.
Christina Shasserre, SVP of Eurofins, stated that the integrated platform will be available for China-based and worldwide clients, adding that the partnership serves both partners’ ‘shared vision’ of accelerating drug development.
